Table 2.
Comparison of Baseline and Injection Data between RPOH and Non-RPOH Patients
| RPOH | P-value | ||
|---|---|---|---|
| Yes (n=26) | No (n=898) | ||
| Age; years | 64 (60–73) | 59 (44–70) | 0.003 |
| Body mass index; kg/m2 | 28 (24–32) | 26 (23–30) | 0.277 |
| Duration of symptoms; months† | 3 (1–6) | 12 (6–36) | <0.001 |
| Female sex; n (%) | 13 (50) | 566 (63) | 0.176 |
| Previous oral steroid use; n (%) | 1 (4) | 44 (5) | 0.795 |
| Fracture on pre-injection imaging; n (%) | 0 (0) | 17 (2) | 0.479 |
| History of autoimmune disease; n (%) | 5 (19) | 144 (16) | 0.405 |
| History of allergies; n (%) | 12 (46) | 461 (51) | 0.602 |
| Low bone density; n (%) | 5 (19) | 117 (13) | 0.357 |
| Additional injections; n (%) | 5 (19) | 197 (22) | 0.742 |
| Triamcinolone in injectate; n (%) | 15 (58) | 464 (52) | 0.545 |
| Methylprednisolone in injectate; n (%) | 10 (38) | 367 (41) | 0.806 |
| Betamethasone in injectate; n (%) | 1 (4) | 63 (7) | 0.530 |
| Dexamethasone in injectate; n (%) | 0 (0) | 4 (0.4) | 0.733 |
| Ultrasound guidance; n (%) | 17 (65) | 573 (64) | 0.869 |
Results are median (interquartile range) for continuous variables and count (percentage) for discrete variables.
RPOH: rapidly progressive osteoarthritis of the hip
†
Duration of symptoms was available for 11 patients with RPOH and 438 patients without RPOH.